Total Payments
$296,383
2024 Payments
$17,550
Companies
19
Transactions
131
Medicare Patients
231
Medicare Billing
$29,269
Payment Breakdown by Category
Consulting$198,781 (67.1%)
Research$73,897 (24.9%)
Other$17,518 (5.9%)
Travel$4,849 (1.6%)
Food & Beverage$1,338 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $198,781 | 51 | 67.1% |
| Unspecified | $73,897 | 24 | 24.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,518 | 4 | 5.9% |
| Travel and Lodging | $4,849 | 17 | 1.6% |
| Food and Beverage | $1,338 | 35 | 0.5% |
Payments by Type
General
$222,486
107 transactions
Research
$73,897
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $47,367 | 31 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $40,600 | 5 | $0 (2017) |
| AstraZeneca UK Limited | $38,940 | 12 | $0 (2018) |
| Alnylam Pharmaceuticals Inc. | $37,148 | 8 | $0 (2024) |
| Takeda Development Center Americas, Inc. | $33,788 | 6 | $0 (2017) |
| Janssen Research & Development, LLC | $32,712 | 12 | $0 (2019) |
| PFIZER INC. | $25,396 | 10 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,133 | 8 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,603 | 16 | $0 (2019) |
| GE HEALTHCARE | $6,619 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,550 | 3 | Alnylam Pharmaceuticals Inc. ($17,550) |
| 2023 | $1,170 | 1 | Alnylam Pharmaceuticals Inc. ($1,170) |
| 2022 | $23.05 | 1 | Kestra Medical Technology Services, Inc. ($23.05) |
| 2020 | $28,507 | 9 | Alnylam Pharmaceuticals Inc. ($18,428) |
| 2019 | $75,682 | 51 | GlaxoSmithKline, LLC. ($35,840) |
| 2018 | $45,185 | 35 | PFIZER INC. ($18,504) |
| 2017 | $128,266 | 31 | Teva Pharmaceuticals USA, Inc. ($40,600) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $8,775.00 | General |
| 01/25/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $7,605.00 | General |
| 01/25/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 08/31/2023 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 07/22/2022 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $23.05 | General |
| Category: Cardiology | ||||||
| 09/24/2020 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Consulting Fee | Cash or cash equivalent | $4,680.00 | General |
| Category: Genetic Disease | ||||||
| 08/18/2020 | Alnylam Pharmaceuticals Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,822.50 | General |
| 08/18/2020 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,755.00 | General |
| Category: Genetic Disease | ||||||
| 08/18/2020 | Alnylam Pharmaceuticals Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,170.00 | General |
| 05/21/2020 | Medtronic Vascular, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,825.00 | General |
| 05/21/2020 | Medtronic Vascular, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,700.00 | General |
| 05/12/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,640.00 | General |
| 02/19/2020 | Astellas Pharma US Inc | LEXISCAN (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: HOSPITAL AND TRANSPLANT | ||||||
| 01/02/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | — | Cash or cash equivalent | $900.00 | Research |
| Study: A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis • Category: Dermatology | ||||||
| 12/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 12/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 12/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 12/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,120.00 | General |
| 12/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,120.00 | General |
| 12/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $560.00 | General |
| 11/17/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $17.58 | General |
| 11/12/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Consulting Fee | Cash or cash equivalent | $8,540.00 | General |
| Category: DIABETES | ||||||
| 11/12/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: DIABETES | ||||||
| 11/12/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: DIABETES | ||||||
| 09/24/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $248.97 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A randomised double blind placebo controlled parallel group multicentre phase III study to evaluate the efficacy and safety of 2 doses of benralizumab MEDI 563 in patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD with a history of COPD exacerbations GALATHEA | AstraZeneca UK Limited | $32,496 | 4 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Development Center Americas, Inc. | $21,463 | 4 |
| A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | GlaxoSmithKline, LLC. | $4,760 | 1 |
| STRATOS 1 Tralokinumab in Asthma Ph 3 Pivotal Study 1, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $4,293 | 2 |
| A Phase 3 Open label Multicentre study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease | GE Healthcare | $3,750 | 1 |
| A PHASE 3 OPEN LABEL MULTICENTRE STUDY OF FLURPIRIDAZ (18F) INJECTION FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR ASSESSMENT OF MYOCARDIAL PERFUSION IN PATIENTS REFERRED FOR INVASIVE CORONARY ANGIOGRAPHY BECAUSE OF SUSPECTED CORONARY ARTERY DISEASE | GE HEALTHCARE | $2,869 | 2 |
| High dose ICS LABA 2ndController Study SIROCCO | AstraZeneca UK Limited | $1,610 | 3 |
| A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis | Sun Pharmaceutical Industries Inc. | $900.00 | 1 |
| A Multicentre Randomized Double blind Parallel Group Placebocontrolled Phase III Efficacy and Safety Study of Benralizumab MEDI 563 Added to High dose Inhaled Corticosteroid Plus Long acting 2 Agonist in Patients with Uncontrolled Asthma CALIMA | AstraZeneca UK Limited | $350.00 | 1 |
| STRATOS 2 Tralokinumab in Asthma Ph 3 Pivotal Study 2, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $191.09 | 2 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Pharmaceuticals U.S.A., Inc. | $13.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 61 | 78 | $8,981 | $6,515 |
| 2021 | 2 | 71 | 117 | $16,140 | $11,675 |
| 2020 | 3 | 99 | 131 | $16,479 | $11,079 |
Total Patients
231
Total Services
326
Medicare Billing
$29,269
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 58 | $8,638 | $6,258 | 72.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 19 | 20 | $342.58 | $257.07 | 75.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 105 | $15,927 | $11,519 | 72.3% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 12 | 12 | $213.12 | $156.31 | 73.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 61 | 88 | $11,173 | $7,392 | 66.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 26 | 31 | $5,259 | $3,652 | 69.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 12 | 12 | $47.28 | $35.40 | 74.9% |
About Dr. Jeffrey Borer, MD
Dr. Jeffrey Borer, MD is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609963792.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Borer, MD has received a total of $296,383 in payments from pharmaceutical and medical device companies, with $17,550 received in 2024. These payments were reported across 131 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($198,781).
As a Medicare-enrolled provider, Borer has provided services to 231 Medicare beneficiaries, totaling 326 services with total Medicare billing of $29,269. Data is available for 3 years (2020–2022), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New York, NY
- Active Since 10/09/2006
- Last Updated 03/10/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1609963792
Products in Payments
- Uloric (Drug) $41,391
- CELEBREX (Drug) $18,475
- INVOKANA (Drug) $10,500
- JARDIANCE (Drug) $9,133
- LAQUINIMOD (Drug) $7,000
- ONPATTRO (Drug) $6,435
- Vascepa (Drug) $5,942
- FASENRA (Drug) $5,540
- ILUMYA (Biological) $900.00
- Mitra Clip system (Device) $126.06
- PRALUENT ALIROCUMAB INJECTION (Biological) $87.50
- Corlanor (Drug) $25.00
- SHINGRIX (Drug) $25.00
- Assure WCD (Device) $23.05
- LEXISCAN (Drug) $14.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Deepak Bhatt, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M